Pyrotinib plus epirubicin and cyclophosphamide followed by docetaxel and trastuzumab as neoadjuvant therapy for HER2-positive early breast cancer: A multicenter non-randomized phase II study
Xiangmei Zhang, Li Wang, Shang Wu, Haifeng Cai et autres
0 citationsBMC Medicine